Anti-inflammatory action of a taurine analogue, ethane-β-sultam, in phagocytic cells in vivo and in vitro.

Roberta Ward, Frederic Lallemand, Philippe De Witte, Robert R. Crichton, Jacques Piette, Keith Tipton, Karl Hemmings, Arnaud Pitard, Michael Page, Laura Della Corte, Deanna Taylor, David Dexter

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The ability of a taurine prodrug, ethane β-sultam, to reduce cellular inflammation has been investigated, in vitro, in primary cultures of alveolar macrophages and an immortilised N9 microglial cell line and in vivo in an animal model of inflammation and control rats. Ethane β-sultam showed enhanced ability to reduce the inflammatory response in alveolar macrophages, as assayed by the lipopolysaccharide-stimulated–nitric oxide release, (LPS stimulated-NO), in comparison to taurine both in vitro (10 nM, 50 nM) and in vivo (0.15 mmol/kg/day by gavage). In addition, ethane β-sultam, (50, 100 and 1000 nM) significantly reduced LPS-stimulated glutamate release from N9 microglial cells to a greater extent than taurine. The anti-inflammatory response of taurine was shown to be mediated via stabilisation of IkBα. The use of a taurine prodrug as therapeutic agents, for the treatment of neurological conditions, such as Parkinson's and Alzheimer's disease and alcoholic brain damage, where activated phagocytic cells contribute to the pathogenesis, may be of great potential.
LanguageEnglish
Pages743-751
Number of pages9
JournalBiochemical Pharmacology
Volume81
Issue number6
Early online date11 Jan 2011
DOIs
Publication statusPublished - 15 Mar 2011

Fingerprint

Ethane
Taurine
Phagocytes
Anti-Inflammatory Agents
Aptitude
Prodrugs
Alveolar Macrophages
Rat control
Inflammation
Parkinson Disease
Lipopolysaccharides
Glutamic Acid
Brain
Alzheimer Disease
Nitric Oxide
Animals
Animal Models
Stabilization
Cells
beta-sultam

Cite this

Ward, R., Lallemand, F., De Witte, P., Crichton, R. R., Piette, J., Tipton, K., ... Dexter, D. (2011). Anti-inflammatory action of a taurine analogue, ethane-β-sultam, in phagocytic cells in vivo and in vitro. Biochemical Pharmacology, 81(6), 743-751. https://doi.org/10.1016/j.bcp.2010.12.030
Ward, Roberta ; Lallemand, Frederic ; De Witte, Philippe ; Crichton, Robert R. ; Piette, Jacques ; Tipton, Keith ; Hemmings, Karl ; Pitard, Arnaud ; Page, Michael ; Della Corte, Laura ; Taylor, Deanna ; Dexter, David. / Anti-inflammatory action of a taurine analogue, ethane-β-sultam, in phagocytic cells in vivo and in vitro. In: Biochemical Pharmacology. 2011 ; Vol. 81, No. 6. pp. 743-751.
@article{d9eb2e3d51644c25b78167329d469e3b,
title = "Anti-inflammatory action of a taurine analogue, ethane-β-sultam, in phagocytic cells in vivo and in vitro.",
abstract = "The ability of a taurine prodrug, ethane β-sultam, to reduce cellular inflammation has been investigated, in vitro, in primary cultures of alveolar macrophages and an immortilised N9 microglial cell line and in vivo in an animal model of inflammation and control rats. Ethane β-sultam showed enhanced ability to reduce the inflammatory response in alveolar macrophages, as assayed by the lipopolysaccharide-stimulated–nitric oxide release, (LPS stimulated-NO), in comparison to taurine both in vitro (10 nM, 50 nM) and in vivo (0.15 mmol/kg/day by gavage). In addition, ethane β-sultam, (50, 100 and 1000 nM) significantly reduced LPS-stimulated glutamate release from N9 microglial cells to a greater extent than taurine. The anti-inflammatory response of taurine was shown to be mediated via stabilisation of IkBα. The use of a taurine prodrug as therapeutic agents, for the treatment of neurological conditions, such as Parkinson's and Alzheimer's disease and alcoholic brain damage, where activated phagocytic cells contribute to the pathogenesis, may be of great potential.",
keywords = "Taurine, Anti-inflammatory action, Ethane-β sultam, Nitric oxide, Glutamate",
author = "Roberta Ward and Frederic Lallemand and {De Witte}, Philippe and Crichton, {Robert R.} and Jacques Piette and Keith Tipton and Karl Hemmings and Arnaud Pitard and Michael Page and {Della Corte}, Laura and Deanna Taylor and David Dexter",
year = "2011",
month = "3",
day = "15",
doi = "10.1016/j.bcp.2010.12.030",
language = "English",
volume = "81",
pages = "743--751",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "6",

}

Ward, R, Lallemand, F, De Witte, P, Crichton, RR, Piette, J, Tipton, K, Hemmings, K, Pitard, A, Page, M, Della Corte, L, Taylor, D & Dexter, D 2011, 'Anti-inflammatory action of a taurine analogue, ethane-β-sultam, in phagocytic cells in vivo and in vitro.', Biochemical Pharmacology, vol. 81, no. 6, pp. 743-751. https://doi.org/10.1016/j.bcp.2010.12.030

Anti-inflammatory action of a taurine analogue, ethane-β-sultam, in phagocytic cells in vivo and in vitro. / Ward, Roberta; Lallemand, Frederic; De Witte, Philippe; Crichton, Robert R.; Piette, Jacques; Tipton, Keith; Hemmings, Karl; Pitard, Arnaud; Page, Michael; Della Corte, Laura; Taylor, Deanna; Dexter, David.

In: Biochemical Pharmacology, Vol. 81, No. 6, 15.03.2011, p. 743-751.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-inflammatory action of a taurine analogue, ethane-β-sultam, in phagocytic cells in vivo and in vitro.

AU - Ward, Roberta

AU - Lallemand, Frederic

AU - De Witte, Philippe

AU - Crichton, Robert R.

AU - Piette, Jacques

AU - Tipton, Keith

AU - Hemmings, Karl

AU - Pitard, Arnaud

AU - Page, Michael

AU - Della Corte, Laura

AU - Taylor, Deanna

AU - Dexter, David

PY - 2011/3/15

Y1 - 2011/3/15

N2 - The ability of a taurine prodrug, ethane β-sultam, to reduce cellular inflammation has been investigated, in vitro, in primary cultures of alveolar macrophages and an immortilised N9 microglial cell line and in vivo in an animal model of inflammation and control rats. Ethane β-sultam showed enhanced ability to reduce the inflammatory response in alveolar macrophages, as assayed by the lipopolysaccharide-stimulated–nitric oxide release, (LPS stimulated-NO), in comparison to taurine both in vitro (10 nM, 50 nM) and in vivo (0.15 mmol/kg/day by gavage). In addition, ethane β-sultam, (50, 100 and 1000 nM) significantly reduced LPS-stimulated glutamate release from N9 microglial cells to a greater extent than taurine. The anti-inflammatory response of taurine was shown to be mediated via stabilisation of IkBα. The use of a taurine prodrug as therapeutic agents, for the treatment of neurological conditions, such as Parkinson's and Alzheimer's disease and alcoholic brain damage, where activated phagocytic cells contribute to the pathogenesis, may be of great potential.

AB - The ability of a taurine prodrug, ethane β-sultam, to reduce cellular inflammation has been investigated, in vitro, in primary cultures of alveolar macrophages and an immortilised N9 microglial cell line and in vivo in an animal model of inflammation and control rats. Ethane β-sultam showed enhanced ability to reduce the inflammatory response in alveolar macrophages, as assayed by the lipopolysaccharide-stimulated–nitric oxide release, (LPS stimulated-NO), in comparison to taurine both in vitro (10 nM, 50 nM) and in vivo (0.15 mmol/kg/day by gavage). In addition, ethane β-sultam, (50, 100 and 1000 nM) significantly reduced LPS-stimulated glutamate release from N9 microglial cells to a greater extent than taurine. The anti-inflammatory response of taurine was shown to be mediated via stabilisation of IkBα. The use of a taurine prodrug as therapeutic agents, for the treatment of neurological conditions, such as Parkinson's and Alzheimer's disease and alcoholic brain damage, where activated phagocytic cells contribute to the pathogenesis, may be of great potential.

KW - Taurine

KW - Anti-inflammatory action

KW - Ethane-β sultam

KW - Nitric oxide

KW - Glutamate

UR - https://www.journals.elsevier.com/biochemical-pharmacology

U2 - 10.1016/j.bcp.2010.12.030

DO - 10.1016/j.bcp.2010.12.030

M3 - Article

VL - 81

SP - 743

EP - 751

JO - Biochemical Pharmacology

T2 - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 6

ER -